Citius Pharmaceuticals Leadership Team – Cranford, NJ

The Citius Pharmaceuticals Leadership Team

Citius’ Leadership Team includes senior pharmaceutical company executives having sustained track records of accomplishment in advancing clinical assets and commercialization of pharmaceutical products, as well as experience in building shareholder value.

Leonard Mazur
Chairman of the Board

Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.

Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.

Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.

Myron Holubiak, President and Chief Executive Officer, Director

Myron Holubiak
President and Chief Executive Officer, Director

Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001. Prior to that, he held sales and marketing positions at Roche during his 19-year tenure there. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016. Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. (“Assembly”) and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.

Gary F. Talarico, EVP, Operations

Gary F. Talarico
EVP, Operations

Mr. Talarico has served as EVP, Operations since March 2016. Mr. Talarico has successfully built and led all commercial activities for a number of start-up companies. Most recently, he was a founder, partner and Executive Vice President of Leonard Meron Biosciences; he was instrumental in acquiring its lead product. Previously, Mr. Talarico served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Mr. Talarico was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, he was Executive Vice President of Business Development for Ventiv Health. His earlier experience included tenures as Vice President of Sales for Medicis Pharmaceutical Corporation at its start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Mr. Talarico is a graduate of Lewis University.

Jaime Bartushak
Chief Financial Officer

Mr. Bartushak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, business development, restructuring, and strategic planning experience. Most recently, in 2014, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc. Mr. Bartushak is also one of the founders of Leonard-Meron Biosciences, and was instrumental in its start-up, as well as obtaining initial investment capital.

Alan Lader, Ph.D., VP, Clinical Operations- citius pharmaceuticals

Alan Lader, PhD
VP, Clinical Operations

Dr. Lader has served as VP, Clinical Operations since March 2016. Dr. Lader has over 25 years of experience in medical research. Prior to joining Citius, Dr. Lader was the Director of Clinical Operations for Ischemix, Inc. Dr. Lader was an Instructor in Medicine at Harvard Medical School and Brigham and Women’s Hospital, where he taught Integrated Human Physiology, and was Principal Investigator for NIH-funded studies in mechanisms of lung cancer metastasis. Dr. Lader has authored over 20 publications in peer-reviewed journals, and has presented more than 20 abstracts at scientific meetings. He received his PhD from the University of South Carolina School of Medicine. He received an MS degree from Rensselaer Polytechnic Institute in Biomedical Engineering and a BS degree in Bioengineering from Syracuse University.

Andrew Scott, VP Corporate Development-citius pharmaceuticals

Andrew Scott
VP, Corporate Development

Mr. Scott has 20 years of transactional experience in strategic planning, product identification, asset acquisition, and capital markets communication. He is a senior investment banker, providing M&A and capital market services to several emerging biotech and pharma companies.